---
title: "Genprex (GNPX) news: reverse split, delisting and Nasdaq notice"
url: "https://aibio.space/companies/genprex/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "GNPX reverse split, delisting and Nasdaq notice news: Genprex plans a 1-for-22 reverse stock split effective July 16. Genprex, Inc."
---

GNPX Genprex, Inc. NASDAQ · United States

# Genprex (GNPX) news GNPX reverse split, delisting and Nasdaq notice news

Company Updates · 2026-10-28

## [Genprex to present TUSC2 aging research at GSA 2026 meeting](https://aibio.space/news/genprex-present-tusc2-aging-research-gsa-2026-meeting/)

A poster from the company's Meharry Medical College collaboration is scheduled for the Gerontological Society of America meeting in National Harbor, Maryland, in November 2026.

## Latest Genprex news

1. 2026-10-21 Company Updates [Genprex reports mouse research linking TUSC2 to healthy brain aging](https://aibio.space/news/genprex-reports-mouse-research-linking-tusc2-healthy-brain-aging/) A peer-reviewed mouse study tied the TUSC2 gene, used in Genprex's REQORSA program, to protein balance and synaptic function in the hippocampus.
2. 2026-08-18 Company Updates [Genprex signs CDMO deal to scale up diabetes gene therapy manufacturing](https://aibio.space/news/genprex-signs-cdmo-deal-scale-up-diabetes-gene-therapy-manufacturing/) The contract manufacturer will make drug product for IND-enabling preclinical studies and future clinical trials of the company's AAV-based diabetes gene therapy.
3. 2026-08-05 Listings [Genprex regains Nasdaq bid price compliance, panel oversight runs to December 7](https://aibio.space/news/genprex-regains-nasdaq-bid-price-compliance-panel-oversight-runs/) Nasdaq's Hearings Panel confirmed on August 4, 2026 that Genprex regained the $1.00 minimum bid price, but the panel keeps jurisdiction until December 7, 2026.
4. 2026-07-30 Listings [Nasdaq panel grants Genprex an exception on the $1.00 bid price rule](https://aibio.space/news/nasdaq-panel-grants-genprex-exception-1-00-bid-price-rule/) The panel's July 29, 2026 decision lets Genprex stay listed on the Nasdaq Capital Market while it keeps a closing bid of at least $1.00 each trading day until December 7, 2026.
5. 2026-07-14 Listings [Genprex plans a 1-for-22 reverse stock split effective July 16](https://aibio.space/news/genprex-plans-1-22-reverse-stock-split-effective-july-16/) The split, approved by the board on July 2, 2026, moves shares outstanding from 11,108,577 to approximately 504,936, and the company released an investor presentation the same day.
6. 2026-06-22 Company Updates [Genprex receives Canadian notice of allowance for REQORSA combination patent](https://aibio.space/news/genprex-receives-canadian-notice-allowance-reqorsa-combination-patent/) The Canadian Intellectual Property Office issued a notice of allowance for a patent covering REQORSA with PD-1 or PD-L1 antibodies in lung cancer.
7. 2026-06-12 Listings [Nasdaq staff says Genprex is not eligible for a bid price compliance period](https://aibio.space/news/nasdaq-staff-says-genprex-not-eligible-bid-price-compliance-period/) A June 10, 2026 Nasdaq letter said Genprex would be delisted unless it requested a hearing, because its stock closed under $1.00 for 30 consecutive business days and it had a reverse split on October 21, 2025.
8. 2026-05-26 Company Updates [Genprex reports ASCO abstract on Trop-2 and PTEN biomarkers for REQORSA](https://aibio.space/news/genprex-reports-asco-abstract-trop-2-pten-biomarkers-reqorsa/) A Genprex-supported abstract at the 2026 ASCO Annual Meeting linked Trop-2 and PTEN protein levels to progression-free survival in non-small cell lung cancer, but not in small cell lung cancer.
9. 2026-05-14 Company Updates [Genprex reports preclinical diabetes gene therapy data at ASGCT](https://aibio.space/news/genprex-reports-preclinical-diabetes-gene-therapy-data-asgct/) Research collaborators presented data showing the company's Pdx1 and MafA gene therapy reversed hyperglycemia in a type 2 diabetes mouse model at the 2026 ASGCT Annual Meeting in Boston.
10. 2025-08-20 Listings [Genprex gets second Nasdaq delisting basis over stockholders' equity, requests hearing](https://aibio.space/news/genprex-gets-second-nasdaq-delisting-basis-stockholders-equity/) Nasdaq says Genprex's equity of $1,391,195 is below the $2.5 million minimum, adding a second basis for delisting to an unresolved bid price failure. A hearing request has stayed any delisting for now.
11. 2025-08-18 Listings [Genprex gets second Nasdaq deficiency notice, with equity at $1,391,195](https://aibio.space/news/genprex-gets-second-nasdaq-deficiency-notice-equity-1-391-195/) Stockholders' equity of $1,391,195 at June 30, 2025 is below the $2.5 million minimum. Genprex has asked for a Nasdaq Hearings Panel hearing, which pauses any delisting while the process runs.
12. 2025-04-01 Distress [Genprex delays 2024 annual report to finish financial statements and audit](https://aibio.space/news/genprex-delays-2024-annual-report-finish-financial-statements-audit/) The company says it needs more time on its 2024 financial statements and audit procedures. Its lead drug, REQORSA, has a Phase 2a trial whose enrollment rules changed twice in 2024 and 2025.

## Genprex at a glance

- **Ticker**: GNPX

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $15.2 million

### Related companies

- [Scopus Biopharma](https://aibio.space/companies/scopus-biopharma/) OTC: SCPS
- [Vertex Pharmaceuticals](https://aibio.space/companies/vertex-pharmaceuticals/) NASDAQ: VRTX
- [ARS Pharmaceuticals](https://aibio.space/companies/ars-pharmaceuticals/) NASDAQ: SPRY
- [Johnson & Johnson](https://aibio.space/companies/johnson-johnson/) NYSE: JNJ
- [EOM Pharmaceutical Holdings](https://aibio.space/companies/eom-pharmaceutical/) OTC: IMUC
- [Pelthos Therapeutics](https://aibio.space/companies/pelthos-therapeutics/) AMEX: PTHS
- [Bioxytran](https://aibio.space/companies/bioxytran/) OTC: BIXT
- [Oruka Therapeutics](https://aibio.space/companies/oruka-therapeutics/) NASDAQ: ORKA

### Also on NASDAQ

- [NewcelX](https://aibio.space/companies/newcelx/) NCEL
- [BGM Group](https://aibio.space/companies/bgm/) BGM
- [Vera Therapeutics](https://aibio.space/companies/vera-therapeutics/) VERA
- [Lifevantage](https://aibio.space/companies/lifevantage/) LFVN
- [PRECISION OPTICS CORPORATION, INC.](https://aibio.space/companies/precision-optics/) POCI
- [VERACYTE, INC.](https://aibio.space/companies/veracyte/) VCYT

## Genprex annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue |  | [$0](https://www.sec.gov/Archives/edgar/data/1595248/000143774925010311/) |
| Research and development | [$9.4 million](https://www.sec.gov/Archives/edgar/data/1595248/000143774926010346/) | [$10.5 million](https://www.sec.gov/Archives/edgar/data/1595248/000143774926010346/) |
| Net income (loss) | [-$16.2 million](https://www.sec.gov/Archives/edgar/data/1595248/000143774926010346/) | [-$21.1 million](https://www.sec.gov/Archives/edgar/data/1595248/000143774926010346/) |
| Cash from operations | [-$15.3 million](https://www.sec.gov/Archives/edgar/data/1595248/000143774926010346/) | [-$17.9 million](https://www.sec.gov/Archives/edgar/data/1595248/000143774926010346/) |
| Cash and equivalents | [$7.8 million](https://www.sec.gov/Archives/edgar/data/1595248/000143774926027846/) | [$1.6 million](https://www.sec.gov/Archives/edgar/data/1595248/000143774926010346/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $15.2 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Genprex

Did Genprex do a reverse stock split?

Our latest story on this, dated Jul 14, 2026: "Genprex plans a 1-for-22 reverse stock split effective July 16". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/genprex-plans-1-22-reverse-stock-split-effective-july-16/).

Was Genprex delisted?

Our latest story on this, dated Jun 12, 2026: "Nasdaq staff says Genprex is not eligible for a bid price compliance period". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nasdaq-staff-says-genprex-not-eligible-bid-price-compliance-period/).

Has Genprex received a Nasdaq deficiency notice?

Our latest story on this, dated Aug 18, 2025: "Genprex gets second Nasdaq deficiency notice, with equity at $1,391,195". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/genprex-gets-second-nasdaq-deficiency-notice-equity-1-391-195/).

What is the ticker symbol of Genprex?

Genprex, Inc. trades under the ticker GNPX on NASDAQ.

Where is Genprex listed?

Genprex, Inc. is listed on NASDAQ. Our directory also records these other listings: LSE:0A8I.

What is the SEC CIK of Genprex?

The SEC Central Index Key (CIK) for Genprex, Inc. is 1595248. Its filings are on SEC EDGAR.

How many shares does Genprex have outstanding?

819,709 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-14.

Which country or territory is Genprex listed under?

Our directory records Genprex, Inc. under United States.

What does Genprex do?

Our directory classifies Genprex, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Genprex?

The ISIN recorded for Genprex, Inc. is US3724464017.

Does aibio.space cover Genprex?

aibio.space lists Genprex, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Genprex incorporated?

SEC records list its state or country of incorporation as TX.

Is Genprex profitable?

Genprex, Inc. reported a net loss of $16.2 million for the fiscal year ended Dec 31, 2025, and used $15.3 million of cash in operations, per its annual report to the SEC.

How much does Genprex spend on research and development?

$9.4 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Genprex have?

$15.2 million in cash at Jun 30, 2026, per its 10-Q.

## Investor discussion: Genprex

Members talk about Genprex (GNPX). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Genprex, newest first. Each line links the filing it comes from.

1. 2026-08-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774926028250/gnpx20260817_8k.htm)
2. 2026-08-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774926025302/gnpx20260802_8k.htm)
3. 2026-07-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774926025074/gnpx20260730_8k.htm)
4. 2026-07-14 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774926023480/gnpx20260630_8k.htm)
5. 2026-06-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774926021262/gnpx20260619_8k.htm)
6. 2026-06-18 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774926021134/gnpx20260615_8k.htm)
7. 2026-06-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774926020501/gnpx20260611_8k.htm)
8. 2026-05-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774926016883/gnpx20260513_8k.htm)
9. 2026-04-29 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774926013906/gnpx20260417_def14a.htm)
10. 2026-04-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774926013534/gnpx20260424_8k.htm)
11. 2026-04-17 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774926012694/gnpx20260402_pre14a.htm)
12. 2026-03-30 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774926010346/gnpx20251231_10k.htm)
13. 2026-02-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774926004954/gnpx20260220_8k.htm)
14. 2026-02-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774926003577/gnpx20260209_8k.htm)
15. 2026-01-09 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774926000995/gnpx20260108_8k.htm)
16. 2025-12-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774925038601/gnpx20251216_8k.htm)
17. 2025-11-26 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774925036380/gnpx20251105_8k.htm)
18. 2025-11-21 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774925036014/gnpx20251120_424b5.htm)
19. 2025-11-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774925035514/gnpx20251116_8k.htm)
20. 2025-11-10 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774925034132/gnpx20251110_424b5.htm)
21. 2025-11-04 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774925032870/gnpx20251024_8k.htm)
22. 2025-10-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774925031856/gnpx20251024c_8k.htm)
23. 2025-10-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774925031572/gnpx20251021d_8k.htm)
24. 2025-10-21 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774925031382/gnpx20251021c_8k.htm)
25. 2025-10-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,3.03,5.03,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774925031210/gnpx20251001_8k.htm)
26. 2025-08-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774925027191/gnpx20250815_8k.htm)
27. 2025-08-15 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774925027138/gnpx20250708c_8k.htm)
28. 2025-07-16 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774925022834/gnpx20250707_def14a.htm)
29. 2025-07-03 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774925022156/gnpx20250314_pre14a.htm)
30. 2025-06-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1595248/000143774925020977/gnpx20250618_8k.htm)

## Press releases

Headlines of Genprex's own announcements, newest first. Each opens the full release on the newswire that carried it.

1. 2026-10-28 PR Newswire [Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting](https://www.prnewswire.com/news-releases/genprex-to-present-tusc2-research-from-sponsored-collaboration-with-meharry-medical-college-at-the-gerontological-society-of-america-2026-annual-scientific-meeting-302921460.html)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:GNPX on TradingView](https://www.tradingview.com/symbols/NASDAQ-GNPX/).

## SEC filings and registration

- **SEC name**: Genprex, Inc.

- **CIK**: 1595248

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: GNPX (Nasdaq)

- **State or country of incorporation**: TX

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 3300 BEE CAVE ROAD SUITE 650-227, AUSTIN, TX, 78746

- **Phone**: 512-537-7997

- **Shares outstanding**: 819,709 as of 2026-08-10 (10-Q filed 2026-08-14)

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1595248/000143774926033053/gnpx20261020_8k.htm) filed 2026-10-21
- [8-K](https://www.sec.gov/Archives/edgar/data/1595248/000143774926028250/gnpx20260817_8k.htm) filed 2026-08-18
- [10-Q](https://www.sec.gov/Archives/edgar/data/1595248/000143774926027846/gnpx20260630_10q.htm) filed 2026-08-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1595248/000143774926025938/gnpx20260805_8k.htm) filed 2026-08-05
- [8-K](https://www.sec.gov/Archives/edgar/data/1595248/000143774926025302/gnpx20260802_8k.htm) filed 2026-08-03
- [8-K](https://www.sec.gov/Archives/edgar/data/1595248/000143774926025074/gnpx20260730_8k.htm) filed 2026-07-30
- [8-K](https://www.sec.gov/Archives/edgar/data/1595248/000143774926023480/gnpx20260630_8k.htm) filed 2026-07-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1595248/000143774926021262/gnpx20260619_8k.htm) filed 2026-06-22

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001595248), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Genprex, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker GNPX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Genprex, Inc.

- **Ticker**: GNPX

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US3724464017

- **Other listed symbols**: LSE:0A8I

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-GNPX/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/genprex/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Genprex (GNPX) news: reverse split, delisting and Nasdaq notice", 2026-10-31, https://aibio.space/companies/genprex/